focus -WSS

focus

author：focus 2025-10-01 00:45:54 - browse：15981

Have you ever taken phenylephrine for a stuffed-up nose and then felt better? If so, you might have been perplexed when Food and Drug Administration experts recently said that that the drug — which is in some versions of DayQuil, Sudafed, and other medicines — is no more effective than a placebo.

But to Michael H. Bernstein, an assistant professor of diagnostic imaging at the Warren Alpert Medical School of Brown University, it all makes sense. Bernstein says that “no better than a placebo” still means that it works, sort of. “If we expect to feel better, then we probably will,” he told me. And that complicates the idea of what medical treatment “works.”

On this episode of the “First Opinion Podcast,” we discuss the placebo effect and its counterpart, the “nocebo effect” — if you tell patients something will make them feel worse, it generally comes true. “You’re better off hearing from a doctor something to the effect of 3 out of 4 patients who take this drug have no side effects at all versus 25% of people who take this drug do get side effects,” he said.

Bernstein also shared the delightful story of how he got into the “medical expectations” field, which started with an experiment in which he had to convince underage students that they were drinking alcohol when they weren’t.

Our conversation was based on a First Opinion Bernstein recently wrote with Grayson L. Baird, “Phenylephrine is no better than a placebo. What if that’s still better than nothing?”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Digital health: a case of mistaken identity

WSS

Headspace, Meta partner to launch VR meditation app for Quest

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Amylyx ALS drug failure raises questions and concerns

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Scrutiny of post

UnitedHealth argues against case alleging wrongful AI care denials

focus

focus

focus

Medical leaders decry Supreme Court decision on affirmative action

Amylyx ALS drug failure raises questions and concerns

Apple is now the first public company to be valued at $3 trillion

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Medicare details structure of new drug price negotiation program

Just how do doctors, lawmakers, and the public define abortion?

Alkermes shareholders re

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Hollywood unions extend contract negotiations for actors

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

focus

H5N1 virus can be tracked in retail milk, scientists say

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Study finds gene variants tied to breast cancer risk in Black women

A deep dive into Applied Therapeutics’ data, and questions on Cassava

CDC marks new Covid

explore

explore

leisure time

leisure time